148 related articles for article (PubMed ID: 34373943)
1. Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC.
Weber D; Decker M; Schuster M; Folz S; Stürmer CJ; Lutz MP
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3769-3771. PubMed ID: 34373943
[TBL] [Abstract][Full Text] [Related]
2. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J
Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177
[TBL] [Abstract][Full Text] [Related]
3. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
[TBL] [Abstract][Full Text] [Related]
4. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
5. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
6. Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
Chun SG; Choe KS; Iyengar P; Yordy JS; Timmerman RD
Cancer Biol Ther; 2012 Dec; 13(14):1376-83. PubMed ID: 22986231
[TBL] [Abstract][Full Text] [Related]
7. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
[TBL] [Abstract][Full Text] [Related]
8. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
9. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
10. The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement.
Bilgin B; Şendur MAN; Yücel Ş; Hizal M; Güner G; Akyürek N; Erol C; Akıncı MB; Dede DŞ; Yalçın B; Kılıçkap S
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2637-2643. PubMed ID: 33528638
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.
Guisier F; Piton N; Bellefleur M; Delberghe N; Avenel G; Angot E; Vittecoq O; Ould-Slimane M; Morisse-Pradier H; Salaun M; Thiberville L
BMC Cancer; 2020 Jan; 20(1):14. PubMed ID: 31906956
[TBL] [Abstract][Full Text] [Related]
12. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
[TBL] [Abstract][Full Text] [Related]
13. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
14. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
Nilsson RJ; Karachaliou N; Berenguer J; Gimenez-Capitan A; Schellen P; Teixido C; Tannous J; Kuiper JL; Drees E; Grabowska M; van Keulen M; Heideman DA; Thunnissen E; Dingemans AM; Viteri S; Tannous BA; Drozdowskyj A; Rosell R; Smit EF; Wurdinger T
Oncotarget; 2016 Jan; 7(1):1066-75. PubMed ID: 26544515
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.
Cao Y; Xiao G; Qiu X; Ye S; Lin T
PLoS One; 2014; 9(12):e114008. PubMed ID: 25501361
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and Safety of Crizotinib in Advanced or Recurrent
ALK-positive Non-small Cell Lung Cancer].
Li X; Xu H; Gao F; Kang X; Zhang J; Zhao J; Lin Y; Liu X
Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):488-493. PubMed ID: 31451138
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
[TBL] [Abstract][Full Text] [Related]
18. Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.
Robesova B; Bajerova M; Hausnerova J; Skrickova J; Tomiskova M; Dvorakova D
Lung Cancer; 2015 Mar; 87(3):318-20. PubMed ID: 25601488
[TBL] [Abstract][Full Text] [Related]
19. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J
Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]